Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CORT
BuyPremium GrowerCorcept Therapeutics Incorporated · Healthcare · United States · $12.3B · Avg Vol: $120M/d
COMPANY DESCRIPTION
Corcept Therapeutics Incorporated is a pharmaceutical company specializing in the discovery and development of cortisol-modulating drugs, with Korlym approved for Cushing's syndrome. The company establishes a strong market position by addressing rare diseases with proprietary treatments. This niche focus and pipeline of selective cortisol modulators provide a competitive edge.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 401.9M | 482.4M | 675.0M | 761.4M | 23.7% | 830.8M | 1.1B | 1.7B | 49.6% |
| EPS | 0.95 | 1.02 | 1.35 | 0.95 | 0.0% | 0.45 | 0.94 | — | -0.6% |
| Shares | 107.8M | 103.4M | 105.1M | 106.0M | -1.7% | 108.1M | — | — | — |
| Debt | 1.1M | 0.2M | 6.9M | 6.1M | 74.8% | 9.4M | — | — | — |
| Equity | 501.8M | 506.7M | 679.6M | 647.8M | 8.9% | — | — | — | — |
| Op CF | 120.3M | 126.7M | 198.3M | 142.0M | 5.7% | 109.7M | — | — | — |
| Inv CF | -114.3M | 90.9M | -177.6M | 69.8M | — | — | — | — | — |
| Fin CF | -17.3M | -148.7M | -28.3M | -220.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CORT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CORT | Corcept Therapeutics Incorporated(you) | $12.3B | 71 | Buy |
| KRYS | Krystal Biotech, Inc. | $10.4B | 74 | Buy |
| TECH | Bio-Techne Corporation | $11.3B | 76 | Buy |
| BMRN | BioMarin Pharmaceutical Inc. | $12.5B | 63 | Hold |
| LGND | Ligand Pharmaceuticals Incorporated | $5.6B | 67 | Buy |
| CAI | Caris Life Sciences, Inc. | $7.2B | 60 | Hold |
| TGTX | TG Therapeutics, Inc. | $8.3B | 57 | Hold |
| HALO | Halozyme Therapeutics, Inc. | $12.0B | 95 | Strong Buy |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.0B | 83 | Strong Buy |
| EXEL | Exelixis, Inc. | $13.5B | 99 | Strong Buy |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.1%